186 related articles for article (PubMed ID: 8451774)
1. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
[TBL] [Abstract][Full Text] [Related]
2. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
Nielsen KK; Brøsen K; Hansen MG; Gram LF
Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
[TBL] [Abstract][Full Text] [Related]
3. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
Skjelbo E; Brøsen K; Hallas J; Gram LF
Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
[TBL] [Abstract][Full Text] [Related]
4. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Drøhse A; Bathum L; Brøsen K; Gram LF
Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
[TBL] [Abstract][Full Text] [Related]
5. The relationship between paroxetine and the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
7. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
Brøsen K; Skjelbo E; Flachs H
Br J Clin Pharmacol; 1993 Aug; 36(2):105-8. PubMed ID: 8398577
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF
Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
[TBL] [Abstract][Full Text] [Related]
9. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Madsen H; Nielsen KK; Brøsen K
Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
[TBL] [Abstract][Full Text] [Related]
10. Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland.
Clasen K; Madsen L; Brøsen K; Albøge K; Misfeldt S; Gram LF
Clin Pharmacol Ther; 1991 Jun; 49(6):624-31. PubMed ID: 2060251
[TBL] [Abstract][Full Text] [Related]
11. Citalopram: interaction studies with levomepromazine, imipramine, and lithium.
Gram LF; Hansen MG; Sindrup SH; Brøsen K; Poulsen JH; Aaes-Jørgensen T; Overø KF
Ther Drug Monit; 1993 Feb; 15(1):18-24. PubMed ID: 8451775
[TBL] [Abstract][Full Text] [Related]
12. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
Inaba T; Jurima M; Nakano M; Kalow W
Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
[TBL] [Abstract][Full Text] [Related]
13. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
Fjordside L; Jeppesen U; Eap CB; Powell K; Baumann P; Brøsen K
Pharmacogenetics; 1999 Feb; 9(1):55-60. PubMed ID: 10208643
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.
Yu BN; Chen GL; He N; Ouyang DS; Chen XP; Liu ZQ; Zhou HH
Drug Metab Dispos; 2003 Oct; 31(10):1255-9. PubMed ID: 12975335
[TBL] [Abstract][Full Text] [Related]
15. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
Schellens JH; van der Wart JH; Brugman M; Breimer DD
J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
[TBL] [Abstract][Full Text] [Related]
16. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
Skjelbo E; Gram LF; Brøsen K
Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
[TBL] [Abstract][Full Text] [Related]
17. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
18. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
19. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study.
Gram LF; Guentert TW; Grange S; Vistisen K; Brøsen K
Clin Pharmacol Ther; 1995 Jun; 57(6):670-7. PubMed ID: 7781267
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Ishizaki T
Clin Pharmacol Ther; 2001 Mar; 69(3):108-13. PubMed ID: 11240974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
